secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-01-10T23:59:59+00:00
Accession:  0001193125-24-005637
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

First pediatric patient dosed with TSHA-102 in REVEAL Phase 1/2 trial for Rett syndrome
--------------------------------------------------------------------------------

- First pediatric patient (female, 5-8 years, stage 3 Rett syndrome) dosed at RUSH University Medical Center.
- MHRA authorized UK CTA for TSHA-102 in pediatric patients, expanding REVEAL into the UK.
- Initial safety and efficacy data for cohort one (low dose, n=3) expected in mid-2024.
- TSHA-102 uses miRARE technology to mediate MECP2 expression on a cell-by-cell basis.
- TSHA-102 also has FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524005637/0001193125-24-005637-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524005637/d674544d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-005637

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer